NASDAQ · XLO

Xilio Therapeutics, Inc.

$8.65 +$0.34 (+4.09%) 1D After hours

Key Metrics

$54.64M
Market cap
P/E · TTM
$53.48M
Revenue · TTM
−$31.30M
Net income
EPS · TTM $-5.87
Dividend yield
Free cash flow −$57.37M
Beta · 1Y 1.04
EBITDA · TTM −$40.86M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 14
    The stock moved +13.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 14
  • Feb 12
    The stock moved +11.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$54.64M
Enterprise value
Shares outstanding6.6M
52-wk range$0.62 – $10.42
Avg volume · 20D479.6K
Net cash
Book value / share$13.60
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Xilio Therapeutics, Inc.
IPO dateOct 22, 2021
Employees76

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.02
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -79.0%
Net -58.5%
FCF -107.3%
ROE / ROIC -69.4% · —

Financial Health

Current ratio3.59
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$111.25M

Cash Flow · TTM

Operating CF −$56.31M
Capex −$1.05M
Free cash flow −$57.37M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-3.0
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings